Lodotra 5 mg

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Lodotra 5 mg

Quick Facts

Property Description
Active Ingredient Prednisone (prodrug)
Form Modified-Release Tablet
Pharmacological Class Glucocorticoid (Corticosteroid)
General Purpose Systemic Anti-inflammatory & Immunosuppressive Action
Origin Synthetic

Identity and Classification: Defining Lodotra 5 mg

Lodotra 5 mg is a synthetic corticosteroid; its active component, Prednisone, is classified as a non-fluorinated glucocorticoid intended for systemic therapy. The medicine utilizes Prednisone as a prodrug, which is a biologically inert substance that must first undergo rapid conversion in the liver into its potent therapeutic form, Prednisolone. This conversion constitutes the drug's essential systemic pathway.

This class of substance is distinguished by its powerful dual pharmacological action as both an anti-inflammatory agent and an immunosuppressive agent. Glucocorticoids are integral to managing widespread inflammatory conditions and modulating immune activity throughout the body.


Form and Function: The Unique Modified-Release Tablet

Lodotra 5 mg is manufactured as a modified-release tablet, a delayed-release oral preparation defined by its controlled-timing formulation. This unique feature is the primary differentiator for this product, setting it apart from standard prednisone formulations.

This specific dosage form utilizes advanced drug delivery technology that ensures the drug is not released immediately upon ingestion, but only after a predetermined delay of approximately four to six hours. This controlled-release mechanism helps achieve peak drug levels later in the day, optimizing the timing of the drug's effect. This functionality fundamentally differentiates Lodotra from conventional, immediate-release prednisone tablets, which achieve rapid concentrations earlier in the bloodstream.


General Therapeutic Goal and Mechanism

The general therapeutic goal of Lodotra is to broadly regulate severe inflammation and immune overactivity throughout the body. The timing of the drug release is specifically optimized to align the peak blood concentration of Prednisolone with the body’s natural circadian fluctuations, which can naturally elevate inflammatory mediators during the late night and early morning hours. By modulating the production and function of immune cells and stabilizing cell membranes, the active substance reduces the symptoms associated with excessive inflammatory and immune responses.

Advertisements

What side effects are possible with Lodotra 5 mg?

Possible Side Effects and Safety Information

This section summarizes the adverse reactions and safety considerations for Lodotra 5 mg as documented in authoritative government regulatory sources.

Adverse Reaction Scope

The safety profile encompasses systemic effects classified across multiple System-Organ Classes due to the medicine’s action. These include: Infections and infestations, Endocrine disorders, Metabolism and nutrition disorders, Psychiatric disorders, Nervous system disorders, Eye disorders, Gastrointestinal disorders, Musculoskeletal and connective tissue disorders, and others.

Frequency Classification Examples of Adverse Reactions (Commonly Reported)
Common Sleep disorder, abdominal discomfort, weight increase, headache, musculoskeletal pain, nasopharyngitis
Not Known The complete range of potential side effects extends across all frequency categories.

Clinically Significant Safety Information

Serious Adverse Reactions and Risks:

  • Acute Adrenal Failure is a risk upon the abrupt cessation of prolonged treatment, especially during periods of stress. Therapy should not be stopped suddenly.
  • Infection Risk is increased, even with low doses and long-term use. The medicine can mask the signs and symptoms of existing or developing infections. Certain viral illnesses, like chickenpox and measles, may take a more severe course.
  • Osteoporosis (weakened bones) with an increased risk of fractures is a noted long-term risk.
  • Worsening of pre-existing severe cardiac insufficiency may occur.

Safety Restrictions and Precautions:

  • The use of this medicine in children and adolescents is not recommended due to insufficient data on tolerability and efficacy.
  • Caution and close monitoring are necessary for patients with certain pre-existing conditions, including diabetes mellitus, severe hypertension, glaucoma, and active viral infections (e.g., Herpes Simplex, Strongyloides infestation).
  • Vaccinations with live vaccines are generally contraindicated during treatment. Inactivated vaccines may have a reduced effect.
  • This modified-release tablet is not to be used for acute indications that typically require immediate-release prednisone.

This official safety documentation establishes that the drug's properties require close monitoring, especially in relation to immune function, endocrine health, and the management of pre-existing conditions, structuring the understanding of its overall risk profile.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Lodotra is a modified-release form of prednisone, which belongs to the class of medicines known as glucocorticoids. Official regulatory information suggests that acute overdosage with glucocorticoids is generally unlikely to lead to acute intoxication that requires immediate medical treatment.

However, a severe or life-threatening situation requires immediate medical attention. If you suspect an overdose, contact emergency medical services or a poison control center right away. Treatment for an overdose is typically supportive and symptomatic.

Overexposure Risks (Chronic/High Dose)

The primary documented risk associated with excessive or prolonged use of Lodotra is related to the cumulative effect of high doses, which can lead to signs of Cushing's syndrome. This condition is caused by exposure to high levels of corticosteroids for an extended period of time.

Overdose Context Official Regulatory Statement Summary
Acute Toxicity Generally unlikely to cause acute intoxication.
Chronic Risk Prolonged use of high doses may lead to Cushing's syndrome.
Emergency Action A severe or life-threatening situation requires immediate medical attention.
Clinical Management Treatment consists of appropriate supportive and symptomatic therapy.

In all cases of suspected overdose or if a severe reaction occurs, professional medical guidance is necessary. It is important to remember that Lodotra is not intended for the treatment of acute medical conditions. Always follow the prescribed dosing regimen exactly.

Advertisements

Therapeutic Uses of Lodotra 5 mg

What Lodotra 5 mg Treats: Main Uses and Benefits

Lodotra is commonly used across conditions presenting with active, moderate to severe Rheumatoid Arthritis (RA) in adults. This medication is considered relevant in clinical settings that involve symptoms related to inflammatory or irritative states where functional stability becomes affected, including widespread joint pain and swelling. The therapy is applied across domains where additional symptomatic support is needed, with relevance in conditions like Rheumatoid Arthritis and Polymyalgia Rheumatica.

Lodotra is particularly applied in addressing circadian-based symptom fluctuations, and is relevant for easing the severity and duration of early morning stiffness that interferes with daily functioning. By providing supportive relief when symptoms become temporarily overwhelming, it generally contributes to improved comfort. “This approach may help patients cope more steadily with symptom fluctuations that peak during the early morning.”

The therapy is commonly used in situations involving certain distressing symptoms, often alongside other long-term disease management strategies, and may assist with maintaining functional stability during symptomatic periods.


Quick Fact: Relief for Morning Stiffness

Feature Therapeutic Focus
Primary Indication Active, moderate to severe Rheumatoid Arthritis
Symptom Cluster Joint pain, swelling, and early morning stiffness
Key Role Plays a role in managing circadian-driven morning symptoms
Context of Use Conditions characterized by periods of heightened systemic symptoms

Regulatory References

  1. Therapeutic Goods Administration (TGA) Australian Public Assessment Report
Advertisements

Eligibility and Restrictions for Use

Eligibility for Use

The official eligibility profile for Lodotra 5 mg confirms that use is established primarily in adults diagnosed with active, moderate to severe rheumatoid arthritis. The regulatory label states that use is not recommended in children and adolescents due to insufficient data on both tolerability and efficacy.

Absolute Contraindications

Lodotra 5 mg is formally contraindicated for several populations. These exclusions include patients with systemic fungal infections or known hypersensitivity to prednisone or any tablet component. It is also contraindicated for individuals with rare hereditary problems, such as galactose intolerance or Lapp lactase deficiency, due to the excipient lactose monohydrate. Patients receiving immunosuppressive doses of this medicine must not be administered live or live attenuated vaccines.

Population-Specific Restrictions

Conditional use and close monitoring are required for populations with specific health conditions. These include patients with renal insufficiency, hypertension, diabetes mellitus, hypothyroidism, or cirrhosis of the liver. Use during the first trimester of pregnancy is explicitly associated with a documented risk of fetal harm.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Lodotra 5 mg is defined by specific pharmacokinetic and pharmacodynamic constraints documented in regulatory labeling.

Timing and Exposure Constraints

The modified-release formulation has a critical, product-specific interaction with food intake. Administration of the tablet with food results in a significant 3- to 4-fold increase in systemic exposure of the active substance. Due to this official pharmacokinetic alteration, the medicine must be taken consistently under fasting conditions.

Metabolic and Drug-Drug Interactions

Co-administration with other medicines may alter systemic exposure through the liver’s CYP 3A4 enzyme pathway. CYP 3A4 inducers, such as Rifampin or Phenytoin, enhance the clearance of the corticosteroid, leading to decreased plasma concentrations. Conversely, CYP 3A4 inhibitors, including Ketoconazole and Ritonavir, may inhibit metabolism, resulting in increased plasma concentrations.

Pharmacodynamic Risk Reinforcement

Certain combinations carry officially documented additive risks. Co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or Salicylates results in an increased risk of serious gastrointestinal side effects. Concurrent use with Potassium-Depleting Agents (e.g., Diuretics) increases the risk of hypokalemia, while combining with Fluoroquinolones is associated with an increased risk of tendon rupture. The corticosteroid may also increase blood glucose concentrations, a factor formally noted to require adjustment of co-administered Antidiabetic Agents.

Advertisements

Mechanism of Action

How Lodotra 5 mg Works

Molecular Control of Inflammatory Gene Expression

Lodotra's active form, prednisolone, acts as an agonist at the intracellular Glucocorticoid Receptor (GRalpha). This interaction leads to transrepression, a mechanism where the drug complex physically blocks key pro-inflammatory transcription factors, primarily Nuclear Factor-κB (NF-κB) and Activator Protein-1 (AP-1), from activating inflammatory genes. This action modifies the early molecular steps that shape systemic physiological outcomes by reducing the synthesis of major inflammatory mediators, such as Interleukin-6 (IL-6) and TNF-alpha.

Chronotherapeutic Synchronization

The drug’s formulation is engineered for chronotherapeutic synchronization, ensuring the highest concentration of prednisolone is delivered to the bloodstream approximately four hours after bedtime. This timing is precisely aligned to coincide with the body’s natural peak surge of inflammatory cytokines that occurs in the early morning hours. This targeted pathway adjustment modulates the effect of the early-morning mediator activity, resulting in a change in the physiological inflammatory signaling.

Advertisements

Dosage and Administration Information

Official Administration Guidelines for Lodotra

Lodotra is a modified-release tablet for oral administration that contains the active substance prednisone. The tablet is designed with a coating to delay the release of prednisone by approximately four to six hours after ingestion, which dictates its specific use protocol.


Administration Scope and Dosing

Instruction Category Official Guideline
Route & Form Oral; modified-release tablet (swallow whole)
Frequency & Timing Once daily, in the evening, usually around 10 pm
Timing in Relation to Meals Take with or after the evening meal; if more than 2–3 hours have passed since the meal, take with a light snack. Do not take in the fasted state.

Procedural Requirements

  • Preparation/Action: Tablets must be swallowed whole with sufficient liquid (e.g., a glass of water). They must not be broken, divided, or chewed because the coating is essential for the delayed-release mechanism to work properly.

  • Dosing Rules: The dosage is individualized based on the patient's condition and response. The typical initial daily dose is 10 mg prednisone. For long-term maintenance, the dose is adjusted to the lowest effective level, typically up to 10 mg daily, and may be reduced in steps of 1 mg every 2–4 weeks.

  • Missed Dose: If you forget a dose, take it as soon as you remember. If you do not remember until the following day, skip the missed dose and take the next dose at the regular time. Do not take a double dose to make up for a forgotten one.

  • Age-Specific Use: Use in children and adolescents is not recommended due to insufficient data on tolerability and efficacy.

This precise administration protocol ensures that the active substance is released during the night, as intended by the delayed-release formulation, which begins approximately four hours after the required bedtime dose.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies

Study 1: Quality of Life in Severe Cases

Research has explored whether the compound may influence the quality of life for participants with severe rheumatoid arthritis (RA). The randomized controlled trials (RCTs) included adults diagnosed with moderate to severe active RA, particularly those with pronounced morning stiffness.

  • Studies evaluated the association between the compound and a reduction in inflammatory markers, such as IL-6 (Interleukin-6), reflecting the circadian rhythm of the underlying inflammation.
  • A study reported changes in pain scores and morning stiffness duration over a 12-week period, using tools like the Visual Analogue Scale (VAS).
  • Adverse events reported in this trial primarily related to gastrointestinal issues, which are common findings with glucocorticoids.

Study 2: Long-Term Management and Combination Use

Research examined the results in participants over periods up to 12 months. This research focused on whether the timed-release formulation, taken at bedtime, could better synchronize the drug's activity with peak morning symptoms compared to immediate-release prednisone taken in the morning.

  • Changes in fatigue scores and sleep quality were noted in follow-up trials.
  • Studies evaluated whether the compound, when compared with immediate-release prednisone, was associated with changes in joint mobility, often measured using disease activity scores (e.g., DAS28).

Summary of Safety and Tolerability Data

Safety and tolerability were evaluated across different adult populations. The most common side effects reported were mild and transient.

  • Research examined outcomes over a period of at least three months, with a high percentage of participants completing the 12-month study period.
  • Data collected from all pivotal trials suggest the most common side effects were mild, primarily headaches and nausea.
  • No new or unexpected safety signals were reported during the trials described above.
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Lodotra 5 mg (FAQ)


Q: How does Lodotra 5 mg differ from other forms of prednisone?

Lodotra is a modified-release tablet, which is its key difference from standard prednisone. This specific formulation is designed to delay the release of the active ingredient by approximately four to six hours after you take it. This timed release helps the medicine reach its highest level in the body later in the day, aligning with the body's natural cycle of inflammation.


Q: Can Lodotra 5 mg be taken with food?

Official guidance states that Lodotra should be taken with or immediately after the evening meal to ensure the medicine works as intended. Taking the tablet under fasting conditions may not allow it to achieve the desired concentration in the bloodstream. The specific way this medicine is taken should always be confirmed with a prescriber.


Q: Does Lodotra 5 mg have a delayed release mechanism?

Yes, Lodotra is specifically designed as a modified-release tablet. This means there is a predictable lag time, typically about four hours, before the release of the active substance begins. This built-in delay is essential for the drug to work according to its chronotherapeutic design.


Q: Can Lodotra 5 mg interact with birth control pills?

Regulatory documents indicate that medicines containing oestrogens, such as oral contraceptives, may increase the effect of glucocorticoids like Lodotra. Patients using oral contraceptives are advised to discuss this potential interaction with their doctor.


Q: Can people with diabetes use Lodotra 5 mg?

Lodotra can be used by people with diabetes, but it requires close medical monitoring. Official product information notes that treatment with Lodotra may increase blood sugar levels. This change in blood sugar may require adjustment to the co-administered anti-diabetic regimen.


Q: Is Lodotra 5 mg considered an immunosuppressant?

Yes. Prednisone, the active ingredient in Lodotra, is classified as a glucocorticoid, which is a type of corticosteroid. This class of medicine is known to have a dual action, functioning as both a powerful anti-inflammatory agent and an immunosuppressive agent to modulate the body's immune activity.


Q: Does Lodotra 5 mg have a different active ingredient than standard prednisone?

No, Lodotra contains the same active ingredient, prednisone, as standard immediate-release prednisone. The difference is solely in the specialized modified-release formulation of the tablet. Like standard prednisone, the drug is converted by the liver into the active therapeutic substance, prednisolone.


Q: Is it okay to crush or split Lodotra 5 mg tablets?

The tablets must be swallowed whole with sufficient liquid and must not be broken, divided, or chewed. Altering the tablet will destroy the delayed-release mechanism, causing the medicine to be released at the wrong time. The tablet’s integrity is crucial for the function described in the official instructions.


Q: Do side effects from Lodotra 5 mg go away over time?

The official product information notes that some side effects may occur early on, while others, such as weight gain, may take longer to develop. Adverse effects associated with this class of medicine may gradually reverse or improve after the medicine is stopped.


Q: Is weight gain common when using Lodotra 5 mg?

Weight increase is listed as a common adverse reaction in regulatory documents. This effect is thought to be related to the medicine's potential to cause increased appetite and fluid retention, which are noted consequences of glucocorticoid use.


Q: Can Lodotra 5 mg cause trouble sleeping?

Yes, 'sleep disorder' is listed as a common adverse reaction for Lodotra. Regulatory supporting documentation indicates that this type of side effect is noted to occur more frequently with this specific modified-release formulation compared to conventional immediate-release versions.


Q: Are there risks associated with drinking alcohol while using Lodotra 5 mg?

Regulatory sources generally advise caution regarding alcohol use while taking prednisone. Official information indicates a potential for increased risk of gastrointestinal side effects when combined with alcohol, and other risks such as mood changes have been reported.


Q: Are there any herbal supplements that should be avoided with Lodotra 5 mg?

It is generally not possible to confirm that herbal remedies or non-regulated supplements are safe to take with prescription medicines like Lodotra. This is because these substances are not tested in the same way as prescription drugs to verify their safety or lack of interaction.


Q: What is the purpose of the 5 mg strength?

The 5 mg strength is one of the available dosage forms. It is essential for allowing the dose to be individualized, which means tailoring it precisely to the patient’s condition and response. The 5 mg tablet is also often used to assist in the process of gradually lowering the dose over time.


Q: Is Lodotra 5 mg known to cause mood changes?

Yes. Official drug safety updates report a wide range of psychiatric reactions associated with this class of medicine. These reactions can include affective disorders, such as feeling irritable, euphoric, depressed, or experiencing a labile (easily changeable) mood. If psychiatric reactions occur, professional medical guidance should be sought.


Q: Can Lodotra 5 mg affect blood pressure?

Yes, Lodotra can affect blood pressure. Because prednisone can cause fluid retention, regular monitoring of blood pressure is officially required for patients who have pre-existing high blood pressure (hypertension).


Q: What are the signs of an allergic reaction to Lodotra 5 mg?

Known hypersensitivity to prednisone is a formal contraindication for use. Signs of an allergic-type reaction may include a rash, swelling (known as edema), or the sudden onset of difficulty breathing. If these signs are noticed, medical attention should be sought promptly.


Q: Can Lodotra 5 mg interact with common cold medicines?

Cold medicines containing certain types of decongestants, known as sympathomimetic agents, should generally be used with caution alongside prednisone. This is due to a documented potential for certain adverse cardiovascular effects, such as blood pressure changes, which may require monitoring.


Q: Is there a maximum time someone can take Lodotra 5 mg?

Official documents do not specify a maximum time for use. However, they emphasize that long-term use of this medicine requires regular medical follow-ups due to noted risks, such as osteoporosis (weakened bones). The duration of therapy depends on the patient's underlying condition.


Q: Can people with kidney problems use Lodotra 5 mg?

Use is permitted, but official regulatory sources state that caution and close monitoring are necessary when corticosteroids, including Lodotra, are prescribed to patients with kidney problems (renal insufficiency). The patient's condition may require close observation by a healthcare professional.


Q: Can Lodotra 5 mg be taken with supplements like Vitamin D?

In official recommendations for long-term therapy, doctors are often advised to implement protective measures against osteoporosis, which includes ensuring a sufficient supply of calcium and Vitamin D. This indicates that supplements like Vitamin D are generally not contraindicated for long-term use.


Q: Does Lodotra 5 mg have a risk of stomach irritation?

While abdominal discomfort is listed as a common side effect, the risk of serious gastrointestinal issues, such as ulcers or bleeding, is officially increased when Lodotra is taken at the same time as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).


Q: What is the half-life of the active ingredient in Lodotra 5 mg?

The active substance that the body converts Lodotra into, called prednisolone, typically has a half-life of about three to four hours. The half-life is the time it takes for half of the drug to be eliminated from the bloodstream.


Q: What is the main difference between Lodotra and Rayos?

Lodotra and Rayos are different brand names for the exact same proprietary medication. Rayos is the brand name used in the United States for the delayed-release prednisone formulation, which is marketed as Lodotra in Europe and other regions.


Q: Is Lodotra 5 mg used for conditions other than rheumatoid arthritis?

While its primary approved use is for active, moderate to severe rheumatoid arthritis, the identical product's regulatory labeling lists approval for a broad range of other inflammatory conditions. These include psoriatic arthritis, ankylosing spondylitis, polymyalgia rheumatica, certain types of lupus, and asthma.


Q: Can Lodotra 5 mg be used during pregnancy?

Official documents state that use during the first trimester of pregnancy is associated with a documented risk of fetal harm. For the later stages of pregnancy, use is determined based on a specific benefit-risk assessment. All decisions regarding use during pregnancy require careful evaluation by a healthcare provider.

Advertisements

How should Lodotra 5 mg be stored and disposed of?

How to Store and Dispose of Lodotra 5 mg

Lodotra 5 mg must be stored and handled according to regulatory requirements to preserve its specialized modified-release formulation. The tablets must be stored at Controlled Room Temperature, which is between 20°C and 25°C (68°F and 77°F), with excursions permitted up to 30°C. The medication must be protected from moisture and light.

Keep Lodotra in its original container and ensure the cap is tightly closed. It is critical not to break, divide, or chew the tablets, as this destroys the delayed-release mechanism. Store the medication out of the reach of children.

Unused or expired tablets should be disposed of properly according to local regulations, preferably by utilizing a medication take-back program. Do not flush Lodotra down the toilet or pour it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lodotra 5 mg found in:

A-Z Index: